Beam Therapeutics · 18 hours ago
mRNA Process Development Co-op
Beam Therapeutics is a biotechnology company focused on precision genetic medicines, and they are seeking a highly motivated Co-op to join their Process Development Team. The Co-op will assist in the development and optimization of linearized plasmid DNA manufacturing processes, including plasmid isolation and purification.
BiotechnologyGeneticsMedicalTherapeutics
Responsibilities
Perform laboratory experiments on plasmid DNA isolation, linearization and chromatographic purification
Assist optimization of reaction parameters for restriction digestion
Run analytical methods including capillary electrophoresis, agarose gel electrophoresis, and high-performance liquid-chromatography to analyze the reaction products and interpret data
Maintain detailed documentation of experiments in the ELN system
Adhere to all laboratory safety requirements and procedures
Qualification
Required
Pursuing a BS/MS/PhD in biological sciences or a related field (Bioengineering, Biochemistry/Biophysics, Cell Biology/Molecular Biology, Chemical Engineering) with at least 1 year of relevant laboratory experience
Knowledge of biochemical & molecular biology methods used in drug discovery and development
Proficient in Excel, PowerPoint, and data analysis
Experience maintaining a lab notebook and following written protocols
Motivated to learn and detail oriented with excellent organizational and communication skills
Company
Beam Therapeutics
Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
H1B Sponsorship
Beam Therapeutics has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (11)
2024 (9)
2023 (12)
2022 (9)
2021 (7)
2020 (4)
Funding
Current Stage
Public CompanyTotal Funding
$1.19BKey Investors
ARCH Venture Partners,F-Prime
2025-03-10Post Ipo Equity· $500M
2021-01-19Post Ipo Equity· $260M
2020-02-11Post Ipo Equity· $207M
Recent News
2026-01-23
2026-01-13
Company data provided by crunchbase